Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

90.38 -5.46 (-5.70%)
Delayed Quote Updated: 2:11 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
News headline image
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick? ↗
Is bigger always better? Not necessarily. 
Via The Motley Fool
News headline image
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100? ↗
BioNTech's cancer pipeline is bigger than its COVID-era reputation suggests, and the stock still trades below $100. 
Via The Motley Fool
News headline image
Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers. 
Via The Motley Fool
Topics Intellectual Property
BioNTech (NASDAQ:BNTX) Falls After Q2 Revenue Miss and Revised Full-Year Guidance ↗
Via Chartmill
BioNTech Q1 2026 Revenue Miss Overshadows Pipeline Progress as NASDAQ:BNTX Slides ↗
Via Chartmill
News headline image
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside? ↗
Moderna has the clinical lead, while BioNTech has the deeper war chest. See which cancer stock offers the stronger long-term setup as mRNA oncology enters a new phase. 
Via The Motley Fool
News headline image
Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success? ↗
The company is looking to prove it can achieve significant success outside the coronavirus market. 
Via The Motley Fool
News headline image
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
Investors buying this biotech stock now will get its pipeline essentially for free. 
Via The Motley Fool
News headline image
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic. 
Via The Motley Fool
News headline image
Why Pfizer Stock Was so Healthy in August ↗
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter. 
Via The Motley Fool
Topics Intellectual Property
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Both have attracted considerable attention from Wall Street recently. 
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
The company is coming back into the spotlight thanks to recent developments. 
Via The Motley Fool
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
BioNTech Just Named a New CEO. Here's What Guido Oelkers' Appointment Means for the Stock. ↗
BioNTech is preparing for its next phase. 
Via The Motley Fool
News headline image
BioNTech (BNTX) Q2 2026 Earnings Call Transcript ↗
COVID vaccine demand weakens as BioNTech pivots to oncology with promising clinical data. 
Via The Motley Fool
Topics Earnings
News headline image
BioNTech Q2 Earnings Call Highlights ↗
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year... 
Via MarketBeat
Topics Earnings
News headline image
BioNTech's Next Act Has Nothing to Do With COVID. Here's the $500 Billion Market Some Investors Are Ignoring ↗
Could it become as successful in this niche as it was in the coronavirus vaccine market? 
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock ↗
Cathie Wood's biotech ETF has largely moved on from the vaccine maker. 
Via The Motley Fool
Topics ETFs
News headline image
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
They may not remain cheap for too much longer. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Biotech Stocks Worth Buying Before Their Potential Buyouts ↗
It has been a banner year for biotech buyouts, and these are two of the prime targets. 
Via The Motley Fool
News headline image
BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM ↗
BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a... 
Via MarketBeat
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Investors can find much better opportunities. 
Via The Motley Fool
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
This may be an excellent deal for those focused on the long game. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Recent performances don't tell the whole story. 
Via The Motley Fool
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
The biotech sector has found its new North Star in 2026. As of mid-March, Moderna Inc. (NASDAQ: MRNA) has shocked Wall Street with a staggering 83% year-to-date gain, catapulting it to the upper... 
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Why BioNTech Stock Is Getting Crushed Today ↗
Nothing about the recent past, present, or foreseeable future seems all that compelling. 
Via The Motley Fool
Gapping stocks in Tuesday's session ↗
Via Chartmill
News headline image
BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier
In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the... 
Via MarketMinute
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
62 63 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.